Pfizer CEO says company will produce 4 billion COVID-19 doses in 2022_老虎社区_美港股上老虎

Pfizer CEO says company will produce 4 billion COVID-19 doses in 2022

Yahoo Finance2021-10-26

Global pressure on just a handful of companies producing COVID-19 vaccines was not the anticipated scenario for fall of 2021. But a series of unfortunate events — including the failure of some vaccine...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

KingPohPoh
·2021-10-26
Nice
回复
1
举报
收起
- HawTK:
  Yes
  2021-10-26
  回复
  举报

热议股票

7x24

全部

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/2178420989?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-10-26 14:47","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2178420989","market":"us","top_or_hot":-1,"title":"Pfizer CEO says company will produce 4 billion COVID-19 doses in 2022","media":"Yahoo Finance","content":"<div>\n<p>Global pressure on just a handful of companies producing COVID-19 vaccines was not the anticipated scenario for fall of 2021. But a series of unfortunate events — including the failure of some vaccine...</p>\n\n<a href=\"https://finance.yahoo.com/news/pfizer-ceo-says-company-will-produce-4-billion-doses-in-2022-164106243.html\">网页链接</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer CEO says company will produce 4 billion COVID-19 doses in 2022</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer CEO says company will produce 4 billion COVID-19 doses in 2022\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-26 14:47 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/pfizer-ceo-says-company-will-produce-4-billion-doses-in-2022-164106243.html><strong>Yahoo Finance</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Global pressure on just a handful of companies producing COVID-19 vaccines was not the anticipated scenario for fall of 2021. But a series of unfortunate events — including the failure of some vaccine...</p>\n\n<a href=\"https://finance.yahoo.com/news/pfizer-ceo-says-company-will-produce-4-billion-doses-in-2022-164106243.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MRNA","symbol_name":"Moderna, Inc.","start_time":0,"source_url":"https://finance.yahoo.com/news/pfizer-ceo-says-company-will-produce-4-billion-doses-in-2022-164106243.html","article_id":"2178420989","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2178420989","pubTimestamp":1635230826,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Global pressure on just a handful of companies producing COVID-19 vaccines was not the anticipated s","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"MRNA":"Moderna, Inc.","PFE":"辉瑞"},"translate_title":"辉瑞首席执行官表示，公司将在2022年生产40亿剂新冠肺炎疫苗","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRNA":0.9,"PFE":0.9},"content_text":"Global pressure on just a handful of companies producing COVID-19 vaccines was not the anticipated scenario for fall of 2021. But a series of unfortunate events — including the failure of some vaccine companies to create or up production and the surge of the Delta variant — have resulted what health equity advocates have long feared: unequal distribution of vaccines among rich and poor countries.\nPfizer (PFE) CEO Albert Bourla told Yahoo Finance the company realized the need and more than doubled its projected output for 2021 as a result.\n\"We changed, dramatically, our strategy. We had invested to produce 1.3 billion doses for 2021, when we realized the situation, we put way more investments into the system and we were able to raise the volumes to 3 billion for this year, and 4 billion for next year,\" Bourla said.\nThe company is also working on a possible treatment for the novel coronavirus. \"I keep my fingers crossed that the studies will be positive, and I hope we'll be able to know if the studies are positive before the end of the year,\" he said.\nPfizer was the first company to receive authorization as well as full approval for adults in the U.S. for its COVID-19 vaccine. It also has a booster dose authorized for certain segments of the population. This action has been criticized by some as doses that are being taken away from the poorer global populations.\nThe company, along with rival Moderna (MRNA), has come under increased pressure by global advocacy groups to produce and donate more doses to the world instead of focusing on boosters in rich countries.\nThe U.S. has promised more than 1 billion doses of COVID-19 vaccines globally, of which about 200 million have been shipped to-date. But experts say more doses are needed.\nPfizer announced plans to open a manufacturing hub with South Africa's Biovac Institute and anticipates it will be operational by early next year. Until then, donating more doses from the U.S. — which is already administering third doses domestically — remains a short-term solution.\nOther countries have also asked to be allowed to donate their unused doses, and recent reports suggest the contract with the company was a barrier.\nBourla told Yahoo Finance that within two days of receiving such a request, Pfizer has been able to work with the country to allow sharing of doses.\nMeanwhile, the Biden administration supports waiving intellectually property (IP) rights, a proposal sent by India and South Africa to the World Trade Organization, to encourage the transfer of technology to middle- and lower-income countries to increase global capacity. Pfizer has maintained that there isn't enough skilled labor in these countries, and in some cases the internal infrastructure in the country is a barrier to equitable distribution.\nIn a recent open letter, Bourla noted that waiving IP would also create unhelpful competition for raw materials.\n\"The proposed waiver for COVID-19 vaccines, threatens to disrupt the flow of raw materials. It will unleash a scramble for the critical inputs we require in order to make a safe and effective vaccine. Entities with little or no experience in manufacturing vaccines are likely to chase the very raw materials we require to scale our production, putting the safety and security of all at risk,\" Bourla said.\nOn Monday, Bourla added that rival Moderna had already offered not to enforce its patent, and couldn't find any takers — highlighting the point that there is, in fact, little additional capacity out there.\nPfizer is now awaiting authorization of its vaccine for kids aged 5-11. A Food and Drug Administration advisory panel is set to meet and discuss the data this week, with an anticipated Centers for Disease Control green light in early November.\nThe vaccine proved 90.7% effective with no concerning side effects reported, according to the data from the company.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":852998364,"gmtCreate":1635231476113,"gmtModify":1635231527454,"author":{"id":"3583810443192023","authorId":"3583810443192023","name":"KingPohPoh","avatar":"https://static.tigerbbs.com/dfce40ecb4c73eaf335eeb992685bc05","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/852998364","repostId":2178420989,"repostType":4,"repost":{"id":"2178420989","pubTimestamp":1635230826,"share":"https://www.laohu8.com/m/news/2178420989?lang=&edition=full","pubTime":"2021-10-26 14:47","market":"us","language":"en","title":"Pfizer CEO says company will produce 4 billion COVID-19 doses in 2022","url":"https://stock-news.laohu8.com/highlight/detail?id=2178420989","media":"Yahoo Finance","summary":"Global pressure on just a handful of companies producing COVID-19 vaccines was not the anticipated s","content":"<p>Global pressure on just a handful of companies producing COVID-19 vaccines was not the anticipated scenario for fall of 2021. But a series of unfortunate events — including the failure of some vaccine companies to create or up production and the surge of the Delta variant — have resulted what health equity advocates have long feared: unequal distribution of vaccines among rich and poor countries.</p>\n<p>Pfizer (PFE) CEO Albert Bourla told Yahoo Finance the company realized the need and more than doubled its projected output for 2021 as a result.</p>\n<p>\"We changed, dramatically, our strategy. We had invested to produce 1.3 billion doses for 2021, when we realized the situation, we put way more investments into the system and we were able to raise the volumes to 3 billion for this year, and 4 billion for next year,\" Bourla said.</p>\n<p>The company is also working on a possible treatment for the novel coronavirus. \"I keep my fingers crossed that the studies will be positive, and I hope we'll be able to know if the studies are positive before the end of the year,\" he said.</p>\n<p>Pfizer was the first company to receive authorization as well as full approval for adults in the U.S. for its COVID-19 vaccine. It also has a booster dose authorized for certain segments of the population. This action has been criticized by some as doses that are being taken away from the poorer global populations.</p>\n<p>The company, along with rival Moderna (MRNA), has come under increased pressure by global advocacy groups to produce and donate more doses to the world instead of focusing on boosters in rich countries.</p>\n<p>The U.S. has promised more than 1 billion doses of COVID-19 vaccines globally, of which about 200 million have been shipped to-date. But experts say more doses are needed.</p>\n<p>Pfizer announced plans to open a manufacturing hub with South Africa's Biovac Institute and anticipates it will be operational by early next year. Until then, donating more doses from the U.S. — which is already administering third doses domestically — remains a short-term solution.</p>\n<p>Other countries have also asked to be allowed to donate their unused doses, and recent reports suggest the contract with the company was a barrier.</p>\n<p>Bourla told Yahoo Finance that within two days of receiving such a request, Pfizer has been able to work with the country to allow sharing of doses.</p>\n<p>Meanwhile, the Biden administration supports waiving intellectually property (IP) rights, a proposal sent by India and South Africa to the World Trade Organization, to encourage the transfer of technology to middle- and lower-income countries to increase global capacity. Pfizer has maintained that there isn't enough skilled labor in these countries, and in some cases the internal infrastructure in the country is a barrier to equitable distribution.</p>\n<p>In a recent open letter, Bourla noted that waiving IP would also create unhelpful competition for raw materials.</p>\n<p>\"The proposed waiver for COVID-19 vaccines, threatens to disrupt the flow of raw materials. It will unleash a scramble for the critical inputs we require in order to make a safe and effective vaccine. Entities with little or no experience in manufacturing vaccines are likely to chase the very raw materials we require to scale our production, putting the safety and security of all at risk,\" Bourla said.</p>\n<p>On Monday, Bourla added that rival Moderna had already offered not to enforce its patent, and couldn't find any takers — highlighting the point that there is, in fact, little additional capacity out there.</p>\n<p>Pfizer is now awaiting authorization of its vaccine for kids aged 5-11. A Food and Drug Administration advisory panel is set to meet and discuss the data this week, with an anticipated Centers for Disease Control green light in early November.</p>\n<p>The vaccine proved 90.7% effective with no concerning side effects reported, according to the data from the company.</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer CEO says company will produce 4 billion COVID-19 doses in 2022</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer CEO says company will produce 4 billion COVID-19 doses in 2022\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-26 14:47 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/pfizer-ceo-says-company-will-produce-4-billion-doses-in-2022-164106243.html><strong>Yahoo Finance</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Global pressure on just a handful of companies producing COVID-19 vaccines was not the anticipated scenario for fall of 2021. But a series of unfortunate events — including the failure of some vaccine...</p>\n\n<a href=\"https://finance.yahoo.com/news/pfizer-ceo-says-company-will-produce-4-billion-doses-in-2022-164106243.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","PFE":"辉瑞"},"source_url":"https://finance.yahoo.com/news/pfizer-ceo-says-company-will-produce-4-billion-doses-in-2022-164106243.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2178420989","content_text":"Global pressure on just a handful of companies producing COVID-19 vaccines was not the anticipated scenario for fall of 2021. But a series of unfortunate events — including the failure of some vaccine companies to create or up production and the surge of the Delta variant — have resulted what health equity advocates have long feared: unequal distribution of vaccines among rich and poor countries.\nPfizer (PFE) CEO Albert Bourla told Yahoo Finance the company realized the need and more than doubled its projected output for 2021 as a result.\n\"We changed, dramatically, our strategy. We had invested to produce 1.3 billion doses for 2021, when we realized the situation, we put way more investments into the system and we were able to raise the volumes to 3 billion for this year, and 4 billion for next year,\" Bourla said.\nThe company is also working on a possible treatment for the novel coronavirus. \"I keep my fingers crossed that the studies will be positive, and I hope we'll be able to know if the studies are positive before the end of the year,\" he said.\nPfizer was the first company to receive authorization as well as full approval for adults in the U.S. for its COVID-19 vaccine. It also has a booster dose authorized for certain segments of the population. This action has been criticized by some as doses that are being taken away from the poorer global populations.\nThe company, along with rival Moderna (MRNA), has come under increased pressure by global advocacy groups to produce and donate more doses to the world instead of focusing on boosters in rich countries.\nThe U.S. has promised more than 1 billion doses of COVID-19 vaccines globally, of which about 200 million have been shipped to-date. But experts say more doses are needed.\nPfizer announced plans to open a manufacturing hub with South Africa's Biovac Institute and anticipates it will be operational by early next year. Until then, donating more doses from the U.S. — which is already administering third doses domestically — remains a short-term solution.\nOther countries have also asked to be allowed to donate their unused doses, and recent reports suggest the contract with the company was a barrier.\nBourla told Yahoo Finance that within two days of receiving such a request, Pfizer has been able to work with the country to allow sharing of doses.\nMeanwhile, the Biden administration supports waiving intellectually property (IP) rights, a proposal sent by India and South Africa to the World Trade Organization, to encourage the transfer of technology to middle- and lower-income countries to increase global capacity. Pfizer has maintained that there isn't enough skilled labor in these countries, and in some cases the internal infrastructure in the country is a barrier to equitable distribution.\nIn a recent open letter, Bourla noted that waiving IP would also create unhelpful competition for raw materials.\n\"The proposed waiver for COVID-19 vaccines, threatens to disrupt the flow of raw materials. It will unleash a scramble for the critical inputs we require in order to make a safe and effective vaccine. Entities with little or no experience in manufacturing vaccines are likely to chase the very raw materials we require to scale our production, putting the safety and security of all at risk,\" Bourla said.\nOn Monday, Bourla added that rival Moderna had already offered not to enforce its patent, and couldn't find any takers — highlighting the point that there is, in fact, little additional capacity out there.\nPfizer is now awaiting authorization of its vaccine for kids aged 5-11. A Food and Drug Administration advisory panel is set to meet and discuss the data this week, with an anticipated Centers for Disease Control green light in early November.\nThe vaccine proved 90.7% effective with no concerning side effects reported, according to the data from the company.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6329838,"gmtCreate":1635232951235,"gmtModify":1635232951270,"authorId":4087822741232210,"author":{"id":4087822741232210,"authorId":4087822741232210,"name":"HawTK","avatar":"https://static.tigerbbs.com/184dd5a8890335d87b5cc27237101a65","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":852998364,"type":1,"supId":0,"prevId":0,"content":"Yes","text":"Yes","html":"Yes"}],"langContent":"CN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":14,"commentSize":1,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}